Study Findings: Risk Model Performance and Finerenone Treatment Effect

The Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) risk models demonstrated effective performance within the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF).

The EMPEROR-Preserved risk models showed effective performance when applied to the FINEARTS-HF trial.

It was observed that the baseline risk did not alter the relative treatment effect of finerenone.